Brian Armstrong’s NewLimit Raises $435M for Human Trials

Cryptonews.net·Jun 3

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

NewLimit, a longevity startup backed by Coinbase CEO Brian Armstrong, has raised $435 million in funding. The company is reportedly working on age-reversing medicine and is expected to use the funds for human trials, with some outlets suggesting a clinical trial may take place as early as 2027. The funding has valued the company at over $3 billion.

Full coverage

Longevity startup NewLimit raises $435 million ahead of first clinical trial

STAT·Jun 2

Coinbase CEO-Backed NewLimit Claims Aging Reversal Breakthrough, Raises $435 Million For Human Trials

Yahoo Finance·Jun 4

Coinbase CEO Brian Armstrong Says His Biotech Company Is Working On 'Extending' Human Lifespan: Here Is How They Plan To Do It

Yahoo Finance·Jan 7

Brian Armstrong’s $435M Gamble Goes Beyond Crypto

FinanceFeeds·Jun 3

View original report at Cryptonews.net ↗

Fetching the latest headlines…

Brian Armstrong’s NewLimit Raises $435M for Human Trials

Full coverage

Longevity startup NewLimit raises $435 million ahead of first clinical trial

Coinbase CEO-Backed NewLimit Claims Aging Reversal Breakthrough, Raises $435 Million For Human Trials

NewLimit raises $435M Series C, valuation hits $3.1B

NewLimit Raises $435M in Series C Funding

Anti-aging startup NewLimit raises $435M at $3B+ valuation, eyes clinic in 2027

NewLimit Raises $435M for Age-Reversing Medicine

Coinbase CEO Brian Armstrong Says His Biotech Company Is Working On 'Extending' Human Lifespan: Here Is How They Plan To Do It

Brian Armstrong’s $435M Gamble Goes Beyond Crypto